Table 3.
Analysis of EGLN3 Methylation in GC tissues and associated clinicopathological factors.
| Characteristics | EGLN3 Methylation | P value | |
|---|---|---|---|
| Low | High | ||
| Age, years | 0.216 | ||
| <65 | 16 | 39 | |
| ≥65 | 2 | 13 | |
| Gender | 0.329 | ||
| Male | 14 | 34 | |
| Female | 4 | 18 | |
| Size, cm | 0.685 | ||
| ≤4 cm | 3 | 6 | |
| >4 cm | 15 | 46 | |
| Tumour location | 0.694 | ||
| Upper 1/3 | 6 | 10 | |
| Middle 1/3 | 5 | 20 | |
| Lower 1/3 | 6 | 19 | |
| More than 2/3 stomach | 1 | 3 | |
| pT stagea | 0.023 | ||
| pT1-2 | 5 | 3 | |
| pT3-4 | 13 | 49 | |
| pN stagea | 0.015 | ||
| pN0 | 6 | 4 | |
| pN+ | 12 | 48 | |
| Lauren type | 0.718 | ||
| Intestinal | 2 | 10 | |
| Diffuse | 16 | 42 | |
apT and pN stage is defined using the American Joint Committee on Cancer (AJCC) Staging System, 8th Edition.